enGene Therapeutics Inc. Warrants financials
$0.2201−35.26%
Close Sep 25, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q3 '26 Jul 31 | Q2 '26 Apr 30 | Q1 '26 Jan 31 | Q4 '25 Oct 31 | Q3 '25 Jul 31 | Q2 '25 Apr 30 | Q1 '25 Jan 31 | Q4 '24 Oct 31 | Q3 '24 Jul 31 | Q2 '24 Apr 30 | Q1 '24 Jan 31 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross margin | — | — | — | — | — | — | — | — | — | — | — |
| Operating income | -$34.0M | -$32.0M | -$31.2M | -$39.5M | -$29.9M | -$27.1M | -$26.6M | -$17.5M | -$16.8M | -$17.3M | -$10.8M |
| Net income | -$32.5M | -$30.2M | -$29.8M | -$37.9M | -$29.0M | -$25.8M | -$24.6M | -$15.3M | -$14.1M | -$15.0M | -$10.7M |
| Net margin | — | — | — | — | — | — | — | — | — | — | — |
| Diluted EPS | $-0.47 | $-0.43 | $-0.44 | $-0.74 | $-0.57 | $-0.51 | $-0.48 | $-0.35 | $-0.32 | $-0.38 | $-0.46 |
| EBITDA | -$33.8M | -$31.8M | -$31.0M | -$39.3M | -$29.8M | -$27.0M | -$26.5M | -$17.4M | -$16.7M | -$17.2M | -$10.7M |
| Operating cash flow | -$18.9M | -$30.5M | -$28.9M | -$25.0M | -$25.6M | -$22.9M | -$25.7M | -$19.6M | -$7.2M | -$14.2M | -$7.4M |
| Free cash flow | -$18.9M | -$30.6M | -$29.1M | -$25.4M | -$26.3M | -$23.0M | -$26.0M | -$19.8M | -$7.2M | -$14.3M | -$7.9M |
| Diluted shares | 69.7M | 69.7M | 67.3M | 51.4M | 51.1M | 51.0M | 51.0M | 44.3M | 44.2M | 39.4M | 23.2M |
Balance sheet
| Period end | Jul 31 | Apr 30 | Jan 31 | Oct 31 | Jul 31 | Apr 30 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $41.0M | $29.8M | $36.6M | $50.2M | $32.6M | $57.5M |
| Short-term investments | $225.3M | $228.6M | $239.3M | $143.6M | $169.3M | $159.8M |
| Total debt | $25.4M | $25.1M | $24.9M | $23.3M | $23.1M | $23.6M |
| Total assets | $288.3M | $307.5M | $337.1M | $221.5M | $245.6M | $266.7M |
| Total liabilities | $58.0M | $52.4M | $55.6M | $53.8M | $44.9M | $39.4M |
| Shareholders' equity | $230.3M | $255.2M | $281.5M | $167.7M | $200.7M | $227.3M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology